Introduction {#s1}
============

The mammalian forkhead box O (FOXO) transcription factor family (FOXO1/FKHR, FOXO3/FKHRL1, FOXO4/AFX, and FOXO6) is involved in multiple cellular processes ranging from apoptosis induction to longevity ([@bib15]). In mammals, FOXO3 and its family members recognize and bind the same core DNA elements (TTGTTTAC) to control the transcription of direct target genes. However, despite sharing the same consensus sequences, FOXO members serve distinct functions and may act as tissue-specific homeostasis regulators.

FOXO3 was initially considered as a tumor suppressor that induces apoptosis and cell-cycle arrest ([@bib4]). However, its functions in cellular detoxification ([@bib6]; [@bib28]), and drug-resistance ([@bib16]; [@bib37]), maintenance of cancer stem cells ([@bib24]) as well as inhibition of other death-inducers such as TP53 ([@bib27]) suggest also a tumor-promoting role in certain types of cancer.

Multiple cellular signaling pathways converge on FOXO3, most importantly the pro-proliferative PI3K-PKB pathway that inactivates target gene transcription. On the other hand, stress conditions, such as genotoxic stress, reactive oxygen species (ROS) or hypoxic stress, override growth-factor-mediated phosphorylation of FOXO3, which results in the relocation of FOXO3 to the nucleus ([@bib8]; [@bib9]). Thereby, stress induced signaling kinases, such as JNK or MST1 that cause FOXO3 activation and nuclear accumulation also in presence of PKB signaling critically contribute to FOXO3-triggered therapy-resistance programs that protect cancer cells during therapy ([@bib11]; [@bib27]; [@bib24]). In addition, FOXO3 regulates the differentiation of naïve regulatory T-cells *via* its transcriptional target FOXP3 ([@bib18]; [@bib13]), which limits the cytotoxic anti-cancer T-cell response by immune-suppressive regulatory T-cells that infiltrate tumor tissue. A reversible inhibition of FOXO3 activity by small compounds thereby might boost anti-tumor immune responses and limit side effects of FOXO3 functional inactivation.

In contrast to the small, defined substrate binding pockets on catalytic enzymes, the DNA binding domain (DBD) of transcription factors are usually regarded as 'undruggable' due to the large surfaces and the fact that the only known ligand is a DNA molecule. Small molecules have been described for the transcription factor FOXM1 ([@bib7]; [@bib14]) and one compound was shown to regulate FOXO1 activity ([@bib23]), but no compounds have been discovered that directly physically interact with the DBD of FOXO proteins to regulate their transcriptional activity. By a pharmacophore model-based, virtual in silico screening approach we identified compound S9 and demonstrate that this molecule inhibits FOXO3-binding to target promoters, affects the cell-wide transcriptional program of FOXO3, as well as FOXO3 effects on cellular ROS-production and cell growth in 2D and 3D cell culture systems. By NMR we demonstrate that S9 directly interacts with FOXO3 DBD, elucidate the mode of binding and how this molecule structurally interferes with FOXO3 transcriptional activity.

Results {#s2}
=======

Identification of compound S9 as FOXO-DBD ligand {#s2-1}
------------------------------------------------

In the absence of known small molecule ligands, a structure-based modeling workflow ([Figure 1a](#fig1){ref-type="fig"}) was developed, employing the crystal structure of FOXO3 DBD in complex with a 13 bp FOXO3 consensus sequence DNA strand (PDB entry 2UZK; [@bib34]). The site to be targeted within the large interaction surface was defined using experimentally observed FOXO3-DNA interactions, consensus sites predicted by four pocket prediction algorithms ([@bib19]; [@bib20]; Pocket-Finder Pocket Detection (<http://www.modelling.leeds.ac.uk/pocketfinder/>), Molecular Operating Environment (MOE, [https://www.chemcomp.com/](https://www.chemcomp.com/Products.htm)), literature data on crucial residues and less flexible sites as suggested by mutational studies and posttranslational modifications ([@bib34]) and a molecular dynamics simulation on the related FOXO4 ([@bib3]), respectively. Due to the limited amount of available data, we aimed to elucidate interaction patterns of potential ligands by combining data from the interactions observed in the protein-DNA complex ([Figure 1b](#fig1){ref-type="fig"}), interaction hotspots on the protein surface calculated with MOE ([Figure 1c](#fig1){ref-type="fig"}), and binding modes predicted by docking of Drugbank ([@bib38]) version 2.5 into the binding site ([Figure 1d](#fig1){ref-type="fig"}). The identified binding patterns were represented by six pharmacophore models, which were subsequently used for virtual screening of the Specs ([www.specs.net](http://www.specs.net)) and Maybridge ([www.maybridge.com](http://www.maybridge.com)) databases. 76 virtual hits for which the desired binding mode was confirmed by further docking studies were selected for experimental testing. Compound S9 (1-(4,6-dimethylpyrimidin-2-yl)−3-(4-propoxyphenyl)guanidine) was identified by pharmacophore model 1 ([Figure 1e](#fig1){ref-type="fig"}).

![Strategy to identify small molecule compounds that interact with FOXO3-DBD.\
(**a**) Overview of the workflow employed to identify FOXO3 inhibitors. (**b**) Interactions between FOXO3-DBD and the 13 bp DNA strand were represented as pharmacophore features. DNA is shown as sticks and FOXO3 DBD residues as lines (left) and the pharmacophore features were mapped onto the FOXO3 DBD protein surface (blue, right). (**c**) Interaction maps highlight areas on the FOXO3 DBD surface (depicted in rose) where the defined probes can interact with the protein. (**d**) Docking poses of DB00878 (magenta), DB02056 (gray), and DB02141 (blue) were used to generate different pharmacophore models. (**e**) Compound S9 maps to one of the pharmacophore models. (**f**) FPA of recombinant FOXO3-DBD (125 nM) and FAM-labeled IRE-oligonucleotide (25 nM). S9 dose-dependent increase of freely rotating oligonucleotide is demonstrated. Shown is the mean of three independent experiments + SD (\*\*\*\*p\<0.0001, \*\*\*p\<0.001). (**g**) PI-staining of nuclei and flow cytometric analyses of SH-EP/FOXO3 cells treated with 50 nM 4OHT alone or in combination with varying concentrations of S9 or S9OX for 48 hr. Shown is the mean + SD of four independent experiments. Statistical differences between 4OHT and S9+4OHT or 4OHT and S9OX+4OHT were assessed by students t-test (\*\*\*p\<0.001, \*\*p\<0.01, two-tailed).](elife-48876-fig1){#fig1}

Primary biochemical validation of hit-compounds was performed via fluorescence polarization analyses (FPA) using recombinant FOXO3-DBD (residues 156--269) and FAM-labeled oligonucleotides containing the IRE consensus sequence (CTA TCA AAA CAA CGC) ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}) in combination with flow cytometric live/dead analyses ([Figure 1---figure supplement 1bc](#fig1s1){ref-type="fig"}). Assay variation of FPA was assessed by calculating Z´ factor ([Figure 1---figure supplement 2d](#fig1s2){ref-type="fig"}: Z´factor = 0.6499). As shown in [Figure 1f](#fig1){ref-type="fig"}, compounds S9 reduced the interaction of FOXO3-DBD to the FAM-IRE oligonucleotide in a dose-dependent manner. We further synthesized an oxalate salt (S9OX) of S9 to improve the solubility of this compound in water ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). To validate these biochemical screening results in living cells we used SH-EP/FOXO3 neuroblastoma cells stably expressing a 4-hydroxy-tamoxifen (4OHT)-regulated FOXO3(A3)ERtm transgene that undergo apoptotic cell death upon activation of FOXO3 ([@bib25]; [@bib11]). As shown in [Figure 1g](#fig1){ref-type="fig"} (and [Figure 1---figure supplement 1bc](#fig1s1){ref-type="fig"}), the addition of compound S9 and S9OX interfered with FOXO3-induced cell death in a dose-dependent manner to similar extent, demonstrating that S9 and the oxalate salt S9OX enter living cells and modulate FOXO3 function. Based on these biochemical and cell-based results we defined S9 as a promising FOXO3-modulatory compound worth for further biochemical, cell biological and structural characterization.

Mapping of the S9-binding site in FOXO3-DBD {#s2-2}
-------------------------------------------

Structural characterization of the interaction between FOXO3-DBD and S9 was performed using NMR spectroscopy. First, ^1^H saturation transfer difference (STD) NMR measurements were used to assess S9 binding to FOXO3-DBD. STD signals were detected for several protons of both S9 and its oxalate salt, thus confirming their interaction with FOXO3-DBD ([Figure 2a](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). In the case of S9OX, pronounced STD signals were observed for H1, H3, H5, and H7 protons, whereas less pronounced signals were observed for H4 and H6 protons. In the case of S9, whose STD spectra were acquired in the presence of 10% DMSO due to its low solubility in water, strong STD signal was observed for H3 protons and less pronounced signals were recorded for H1, H5, H6 and H7 protons. These data suggested that both aromatic moieties as well as the aliphatic part of S9 are involved in direct interactions with FOXO3-DBD.

![Compounds S9/S9OX block the DNA binding surface of FOXO3-DBD.\
(**a**) 1D ^1^H STD-NMR experiments for S9OX compound in the presence of the 15 µM FOXO3-DBD. The reference spectrum of S9OX is shown in black, the corresponding STD-NMR spectrum is shown in red. Hydrogens in S9 are numbered from 1 to 7. (**b**) The summary of quantified chemical shift perturbations (CSPs) obtained for the FOXO3-DBD in the presence of 1.5 mM S9OX. The changes in chemical shift resonances were calculated using weighted combination of chemical shifts given by: $CSP = \sqrt{{\Delta\delta}_{H}^{2} + \left( \frac{1}{5}{\Delta\delta}_{N} \right)^{2}}$, where Δδ~H~ and Δδ~N~ are differences in chemical shifts of ^1^H and ^15^N, respectively, in the free and bound states ([@bib36]). The relative CSPs were obtained by dividing absolute CSP values by a standard deviation of the whole set of CSPs. The regions of the protein backbone that could not be unambiguously assigned are highlighted in gray. The secondary structure of FOXO3-DBD is indicated on top. The dotted and dashed lines indicate changes greater than the mean and the mean + 1σ^0^~corr~, respectively. (**c**) Observed CSPs mapped onto the solution structure of FOXO3-DBD ([@bib35]). Ribbon and surface representations are shown at right and left, respectively. Thirteen residues whose ^1^H-^15^N resonances were significantly perturbed (1σ^0^~corr~ above the mean) are shown in red. Selected signals from the ^1^H-^15^N HSQC spectra of 250 μM FOXO3-DBD in the presence of various concentrations of S9OX are shown in inset. (**d**) Structural model of FOXO3-DBD with bound S9. The best flexible docking solution consistent with data from ^1^H-^15^N HSQC and STD measurements is shown.](elife-48876-fig2){#fig2}

Because the previously published NMR sequential assignment of human FOXO3-DBD ([@bib35]) was obtained for shorter construct (residues 151--251) compared to the construct used in this study (residues 156--269), standard triple resonance experiments were used to obtain a sequence specific backbone assignment of our FOXO3-DBD~156-269~ construct. The ^1^H-^15^N heteronuclear single quantum coherence (HSQC) spectrum of ^15^N-labeled FOXO3-DBD with obtained resonance assignment is shown in [Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}. The data analysis provided a resonance assignment for 99 out of 114 residues (87% of the FOXO3-DBD sequence). To identify the S9-binding site in FOXO3-DBD, the ^15^N-labeled FOXO3-DBD was titrated with S9OX and ^1^H and ^15^N chemical shift perturbations (CSPs) of the backbone amide groups of FOXO3-DBD were followed in ^1^H-^15^N HSQC spectra ([Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"}). The oxalate salt of S9 was used for its higher solubility in water, thus avoiding the use of DMSO and the associated chemical interferences. The presence of S9OX induced significant dose-dependent CSPs of backbone amide groups of fifteen FOXO3-DBD residues (the chemical shift change was greater than σ^0^~corr~ above the mean), thus suggesting their involvement in the interaction or their conformational change induced by S9 binding ([Figure 2b](#fig2){ref-type="fig"}). When these residues were mapped onto the solution structure of FOXO3-DBD ([@bib35]), they revealed the binding surface for S9 in the region formed by the DNA recognition α-helix H3 and the N-terminal part of β-strand S2 ([Figure 2c](#fig2){ref-type="fig"}). The most affected residues (the chemical shift change was greater than 2σ^0^~corr~ above the mean) were Arg211, His212, Asn213, Ser215 and Leu216 from the helix H3; Phe220 and Asn237 from the wing W2; and Thr167 from the helix H1. In addition, the gradual shift of resonances during titration indicated fast exchange of the ligand on the NMR time scale, thus suggesting that the S9OX binding is of moderate affinity.

To obtain greater insight into the interaction of S9 with FOXO3-DBD, docking calculations using Autodock Vina ([@bib33]) were performed. The S9 binding surface (the residues whose side-chains were treated as flexible) included residues identified in ^1^H-^15^N HSQC experiment as well as several additional residues with high CSPs located close to them ([Figure 2d](#fig2){ref-type="fig"}). The calculated poses with the lowest binding energy were extracted and further validated against results from STD NMR measurements. The final pose is consistent with results from both STD and ^1^H-^15^N HSQC experiments and suggests that S9 binds into the groove formed by residues Arg211, His212 and Ser215 at the C-terminus of α-helix H3 and residues Met221 and Arg222 from the N-terminus of β-strand S2. This region is a crucial part of the FOXO3-DBD/DNA interface as the DNA recognition α-helix H3 is responsible for most of the direct base contacts with DNA and the N-terminal part of β-strand S2 is involved in contacts with the DNA backbone ([@bib34]). Therefore, these data indicate that S9 binding blocks the DNA binding surface of FOXO3-DBD in the region of the recognition α-helix H3.

Compounds S9 and S9OX affect the FOXO3 transcriptional program {#s2-3}
--------------------------------------------------------------

To analyze the effect of compound S9 on mRNA steady state levels of FOXO3-regulated genes we assessed genome-wide regulatory events by mRNA expression profiling. SH-EP/FOXO3 cells were treated with 50 nM 4OHT for three hours in presence or absence of 50 µM compound S9 and the transcriptome was measured with Affymetrix U133 2.0 whole genome chips. 1262 probesets were induced and 889 probesets showed statistically significant repression upon activation of ectopic FOXO3(A3)ERtm as demonstrated in heatmaps ([Figure 3a](#fig3){ref-type="fig"}) and volcano blots ([Figure 3b](#fig3){ref-type="fig"}). When 4OHT-driven activation of ectopic FOXO3 was combined with S9, the gene induction was much less pronounced, with the expression of only 208 probesets upregulated of which 35 were common with FOXO3 activation alone ([Figure 3c](#fig3){ref-type="fig"}). We examined whether the presence of S9 reversed FOXO3-mediated gene induction and identified 193 probesets showing significant repression in presence of S9, suggesting an inhibition of FOXO3-mediated induction ([Figure 3b](#fig3){ref-type="fig"}). Furthermore, 779 probesets have shown the reversal of expression although they did not reach statistical significance. This suggests that S9 inhibited FOXO3-mediated induction of the majority of mRNAs (77% of FOXO3 induced probesets overall, 15% statistically significant). We also observed an increase in steady state levels of 173 probesets that were not regulated by ectopic FOXO3. These changes in mRNA expression might result from differences in target gene regulation between ectopic FOXO3(A3)ERtm and endogenous FOXO3, as ectopic FOXO3(A3)ERtm carries mutations at the major PKB phosphorylation sites (T32, S253 and S315) or off-target effects. This effect of S9 is well visualized in the heatmap analysis ([Figure 3a](#fig3){ref-type="fig"}) where S9 attenuates the strong induction of a large cluster of genes (top-part of heatmaps) or repressed highly expressed FOXO3 targets by its own (bottom part of heat map), suggesting inhibition of endogenous FOXO3. Interestingly, S9 alone also induced a cluster of strongly repressed FOXO3-targets (middle part of heatmaps) and, for a small number of genes, S9 increased FOXO3-mediated induction (arrows). When comparing S9 with DMSO control, 412 probesets were repressed. Therefore, although S9 mainly exerts an inhibitory effect on FOXO3 transcriptional activity, this compound also induces mRNA expression of a small number of FOXO3 target genes.

![Compounds S9/S9OX affect induction of FOXO3 target gene mRNAs.\
(**a**) Heatmaps of Affymetrix microarray analyses (U133 plus 2.0 expression profiling chips). Total RNA was prepared of SH-EP/FOXO3 cells treated with 100 nM 4OHT alone or in combination with 50 µM S9 for three hours. Expression heatmap shows average expression of the differentially expressed genes within three replicates in each condition. The rows were scaled around 0. (**b**) Left volcano blot shows log2 fold changes of all probesets on the microarray on x-axis and the significance level (-log10(p-value)) on the y-axis -- probesets significantly induced by FOXO3 are in red. The right volcano blot shows log2 fold change of S9+4OHT as compared to FOXO3-induced probesets. (**c**) Venn diagram showing numbers of genes regulated in common when cells with activated FOXO3 were treated with S9 or solvent as control. (**d**) NOXA, (**e**) BIM, (**f**) SESN3, and (**g**) DEPP1 mRNA levels were measured by quantitative RT-PCR in SH-EP/FOXO3 cells after treatment with 100 nM 4OHT for three hours alone or in combination with 50 µM S9 or S9OX (cells were preincubated with compounds for 30 min). Bars represent mean + SD of three independent experiments, each performed in triplicates (untreated control was set as 100%). Significant differences between 4OHT treatment and S9+4OHT or S9OX+4OHT: \*p\<0.05, \*\*p\<0.01 (students t-test, two-tailed).](elife-48876-fig3){#fig3}

To verify genome-wide gene expression results we selected four genes previously identified as FOXO3 targets in neuroblastoma cells and evaluated the effect of compound S9 and its oxalate salt S9OX on mRNA expression by quantitative RT-PCR analyses. As shown in [Figure 3d--g](#fig3){ref-type="fig"}, activation of ectopically-expressed FOXO3(A3)ERtm by 4OHT significantly induced steady state expression of the pro-apoptotic BH3-only proteins BIM and NOXA, as well as of the detoxifying proteins SESN3 and DEPP1 similar to previously published data from our group ([@bib8]; [@bib25]; [@bib28]; [@bib29]). S9 or S9OX alone caused no statistically significant changes in steady state expression of these genes compared to solvent-treated controls. However, when combined with activation of ectopic FOXO3, S9 as well S9OX significantly counteracted mRNA induction of all four *bona fide* FOXO3 targets suggesting that this compound efficiently interferes with specific mRNA induction by FOXO3.

FOXO3-modulatory compounds S9 and S9OX inhibit the induction of FOXO3 target proteins, binding of FOXO3 to target promoters and promoter transactivation {#s2-4}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we quantified the effects of compound S9 and S9OX by immunoblot analyses to assess whether regulations observed on mRNA steady state level were also translated into changes in protein expression. As shown in [Figure 4a--d](#fig4){ref-type="fig"} the activation of the 4OHT-regulated FOXO3(A3)ERtm transgene in SH-EP/FOXO3 neuroblastoma cells elevated the protein levels of the proteins BIM, NOXA, SESN3 and DEPP1. Consistent with quantitative RT-PCR results in [Figure 3d--g](#fig3){ref-type="fig"}, both S9 and S9OX prevented FOXO3-mediated induction of NOXA, BIM and SESN3 above background level and significantly attenuated the strong induction of DEPP1, demonstrating that S9 and S9OX efficiently interfere with the regulation of FOXO3 target proteins in living cells. The combined data suggest that S9 and S9OX both modulate FOXO3-transcriptional program and target protein regulation. Biochemical results from FPA and NMR-based structural analyses suggest that in vitro the compounds S9/S9OX bind to the DBD of FOXO3 and inhibit DBD -- DNA interaction. To address, whether S9 directly interferes with FOXO3 target promoter recognition in living cells we next performed chromatin immunoprecipitation (ChIP) analyses and assessed the binding of FOXO3 to the promoters of BIM, NOXA, SESN3 and DEPP1. As demonstrated in [Figure 4e](#fig4){ref-type="fig"}, activation of the conditional FOXO3 allele for three hours significantly increased FOXO3 promoter binding, which is consistent with the previously demonstrated induction of these FOXO3 targets on mRNA and protein level. Importantly, for all investigated promoters, the addition of S9 almost completely reduced the interaction of FOXO3 with endogenous promoters to control level. To assess, whether this reduced promoter binding also correlates with reduced transactivation we used a luciferase reporter vector containing a 544 bp DEPP1 promoter fragment that carries three putative FOXO3 consensus sites ([@bib28]). As demonstrated in [Figure 4f](#fig4){ref-type="fig"}, compound S9 reduced luciferase activity in a dose-dependent manner with approximately 50% reduction at 12.5 µM. These results confirm the biochemical binding studies between compounds S9 and S9OX and FOXO3-DBD ([Figure 1f](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"} and [Figure 2](#fig2){ref-type="fig"}) and demonstrate that S9 inhibits binding of FOXO3 to target promoters and their activation in living cells.

![Compounds S9 and S9OX inhibit protein expression of FOXO3-regulated proteins and prevent binding of FOXO3 to target promoters.\
SH-EP/FOXO3 cells were treated for eight hours (**a,b**) or 24 hr (**c,d**) with 100 nM 4OHT alone or in combination with 50 µM S9 or S9OX. Cell lysates were subjected to immunoblot analyses using antibodies against NOXA and BIM (8 hr) or SESN3 and DEPP1 (24 hr). Shown are representative immunoblots (**a,c**) or densitometric analyses of three independent cell lysates mean values + SD. Regulations are expressed as fold over DMSO-control (100%). Significant differences between 4OHT treatment and S9+4OHT or S9OX+4OHT were analyzed by students t-test: \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; two-tailed. (**e**) ChIP analyses were performed in SH-EP/FOXO3 cells treated with 100 nM 4OHT for three hours alone or in combination with 50 µM S9. Binding of FOXO3 to the promoter regions of BIM, NOXA, SESN3, and DEPP1 was measured by quantitative PCR. Shown is the mean value + SD of three independent experiments, each performed in duplicates. Significantly different to untreated cells: \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, two-tailed. (**f**) Binding of FOXO3 to the promoter region of DEPP1 was assessed after transfection of a DEPP1-luciferase reporter plasmid into SH-EP/FOXO3 cells. 24 hr after transfection cells were seeded into 24 well plates. After adherence for another 24 hr, cells were treated for three hours with 100 nM 4OHT with or without increasing amounts of S9 (preincubated for 30 min). Firefly-luciferase was analyzed using the Luciferase Assay System (Promega). The increase of light emission (relative light units, RLU) was calculated as percent of untreated controls. Shown are mean values + SD of four independent experiments, each performed in triplicate. Significant differences between 4OHT treatment and S9+4OHT: \*p\<0.05, \*\*p\<0.01 (students t-test, two-tailed).](elife-48876-fig4){#fig4}

Selectivity of compound S9/S9OX for FOXO transcription factors {#s2-5}
--------------------------------------------------------------

In above experiments we demonstrated that the in silico identified S9 compound physically interacts with FOXO3-DBD and affects binding to FOXO3 responsive promoters as well as FOXO3 gene regulation in a cell system with a conditionally activated ectopic FOXO3 allele. We next investigated whether S9 can still modulate FOXO3 effects in a cell system with a 4OHT-activated FOXO3(A3)-H212R-ERtm mutant. H212 is strongly affected by binding of S9 ([Figure 2b](#fig2){ref-type="fig"}) suggesting that this amino acid critically participates in S9 binding. As demonstrated in [Figure 5a](#fig5){ref-type="fig"} activation of FOXO3(A3)-H212R still induced apoptotic cell death in SH-EP cells although to a significantly lower extent than the FOXO3(A3) construct. However, in contrast to FOXO3(A3)-induced cell death, S9 did not affect apoptosis by the FOXO3(A3)-H212R mutant suggesting that the H212 mutation completely abrogates FOXO3-inhibitory effects of S9. As to this point all experiments were done using ectopically expressed, conditional FOXO3(A3) alleles we next tested whether S9 might also interfere with the regulation of target genes by endogenous FOXO3 in response to chemotherapeutics and/or serum withdrawal. Using CRISPR/Cas9 technology we generated FOXO3 knockout cell lines that completely lack endogenous FOXO3, transiently transfected luciferase reporter plasmids for BIM and DEPP1 and treated these cells with etoposide (after serum withdrawal) to activate endogenous FOXO3 ([@bib8]). As shown in [Figure 5bc](#fig5){ref-type="fig"}, etoposide treatment increases promoter activity of the BIM and the DEPP1 promoter two- to threefold and S9 completely prevents this induction. Knockout of endogenous FOXO3 abrogates the effect of etoposide treatment on FOXO3-responsive promoters and S9 does not further affect promoter activity suggesting that the inhibitory effect of S9 depends on the presence of endogenous FOXO3 protein and is not due to unspecific effects on transcription. To assess this question further on endogenous expression of FOXO3 target genes we analyzed expression levels of BIM, DEPP1 and SESN3 by qRT-PCR under conditions of etoposide treatment and/or serum withdrawal (0.5% FBS). Serum withdrawal significantly increased expression of DEPP1 and SESN3 and additional treatment with etoposide strongly induced the expression of all three target genes. In FOXO3 knockout cells, still some increase of DEPP1 and SESN3 expression was observed which was not affected by S9. The strong induction of all three genes by a combination of serum-withdrawal and etoposide treatment, which was efficiently inhibited by S9 was also almost completely abrogated by FOXO3 knockout. The combined data clearly demonstrate that S9 transcriptional inhibition of FOXO target genes depends on the presence of cellular FOXO3. To further assess the selectivity of S9 within forkhead proteins and in specific FOXO family members in vitro we established and performed FP assays with recombinant FOXO1-DBD (159-272), FOXO3-DBD, FOXO4-DBD (82-207) and FOXO6-DBD (87-200) as well as with FOXM1-DBD (222 - 360). As demonstrated in [Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}, at a concentration of 250 nM, S9 most efficiently displaced the FAM-labelled IRE-oligonucleotide from FOXO3-DBD and FOXO4-DBD and had a less pronounced effect on FOXO1-DBD. Interestingly, the substance did not interfere with FOXO6-DBD -- DNA binding at all. Differential binding/selectivity for FOXO-family members might be explained by the fact that although the amino acid sequences of FOXO-DBDs are highly homologous, NMR solution structures reveal significant differences between the DBDs of these closely related proteins ([@bib26]). To assess whether S9 might exert effects by binding to other important forkhead proteins such as FOXM1 we also established an FP-assay for the FOXM1-DBD, analyzed S9 effects at 500 nM and observed no effect on FOXM1-DBD -- DNA interaction ([Figure 1---figure supplement 2b](#fig1s2){ref-type="fig"}). To further complement these analyses with direct binding studies we performed NMR spectroscopy measurements which demonstrated differential effects of S9OX on ^1^H and ^15^N chemical shift perturbations of backbone amide groups in ^15^N-labeled FOXO1-DBD, FOXO3-DBD and FOXO4-DBD proteins ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

![Selectivity assessment of S9 and S9OX for FOXO3.\
SH-EP cells expressing a conditionally activated FOXO3(A3)-ERtm-H212R mutant or FOXO(A3)-ERtm were analyzed by immunoblot, treated with 20 nM 4OHT with or without 50 µM S9 or S9OX and subjected to flow cytometric cell death analyses after 48 hr (**a**). Shown is the mean of four independent experiments (two-tailed students t-test: \#\#p\<0.01, \*\*\*p\<0.001). To assess whether S9- or S9OX-mediated inhibition of FOXO target gene regulation relies on endogenous FOXO3 we generated FOXO3 knock-out cells using CRISPR/Cas9 technology. Immunoblot demonstrates complete loss of endogenous FOXO3 expression in lines \#1 and \#2. SH-EP/crispCtr and SH-EP/crispFOXO3\#1 and \#2 cells were transfected with either a Bim-promoter-, a DEPP1-promoter-, or control luciferase reporter plasmid. 24 hr after transfection cells were seeded into 24 wells and kept under 0.5% FBS for 16 hr. Pre-incubation (30 min) with 50 µM S9 or S9OX was performed before 20 µg/ml etoposide were applied for three hours. Luciferase-activity of Bim- and DEPP1-promoters was assessed using Luciferase Assay System (Promega) according to manufacturer's instructions. RLU were normalized to control luciferase reporter and expressed as % of control. Shown is the mean of three independent experiments (two-tailed students t-test: \#p\<0.05, \#\#p\<0.01, \*p\<0.05, \*\*p\<0.01; **b, c**). SH-EP/crispCtr and SH-EP/crispFOXO3\#1 and \#2 cell lines were kept at 10% FCS or 0.5% FCS for 16 hr, treated for 30 min with 50 µM of compounds S9 and then for another three hours with 20 µg/ml etoposide as indicated. Effect of endogenous expression of Bim (**d**), DEPP1 (**e**) and SESN3 (**f**) was assessed by quantitative RT-PCR. Shown is the mean of three independent experiments each performed in triplicate (two-tailed students t-test: \#p\<0.05, \#\#p\<0.01, \#\#\#p\<0.001, +p\<0.05, ++p\<0.01, \*p\<0.05, \*\*p\<0.01, §\<0.05).](elife-48876-fig5){#fig5}

Compounds S9 and S9OX prevent ROS-induction and cell death by FOXO3 in 2D and 3D cell culture models {#s2-6}
----------------------------------------------------------------------------------------------------

We previously demonstrated that FOXO3-activation induces a bi-phasic reactive oxygen species (ROS) wave that critically contributes to induction of apoptotic cell death in human neuroblastoma cells ([@bib8]). To assess the effect of S9 and S9OX on ROS accumulation by FOXO3 we either activated ectopic FOXO3(A3)ERtm by 4OHT treatment ([Figure 6a](#fig6){ref-type="fig"}) or treated the cells with 20 µg/ml etoposide to activate endogenous FOXO3 *via* DNA-damage response ([Figure 6b](#fig6){ref-type="fig"}). Direct activation of ectopic FOXO3 by 4OHT or etoposide treatment cause significant accumulation of cellular ROS as demonstrated by live-cell fluorescence microscopy using the ROS-sensitive dye reduced mitotracker red. Both S9 and S9OX completely prevent ROS accumulation in 4OHT- and etoposide-treated cells demonstrating that S9 and S9OX efficiently prevent cellular ROS accumulation in response to FOXO3 activation. Since results obtained with 2D cell culture only partially reflect effects of compound treatment in tissues or solid tumors we assessed the effect of S9 and its oxalate salt S9OX in 3D spheroids of neuroblastoma cells formed by magnetic bioprinting and magnetic levitation culture. For these experiments the FOXO3-sensitive, high-stage neuroblastoma cell line NB15/FOXO3-GFP was used to directly image cell growth/viability by fluorescence microscopy. To define at which concentrations S9 and S9OX are still biologically active and how long physiologic effects may be observed upon single treatment we reduced the concentrations of S9 and S9OX to 5 µM. Tumor spheres grown for 72 hr floating in a magnetic field were treated with 10 nM 4OHT for 72 hr in presence or absence of S9 and S9OX and then cultured for another week. After this time, sphere-size and number of spheres per well were analyzed by fluorescence microscopy ([Figure 6c--e](#fig6){ref-type="fig"}). Metabolic activity and cell viability were assessed by measuring ATP-content ([Figure 6f](#fig6){ref-type="fig"}) and reduction of resazurin salt ([Figure 6g](#fig6){ref-type="fig"}), respectively. Both, S9 and S9OX prevented FOXO3-induced cell death in 3D tumor spheroids at a concentration of 5 µM and after single administration. Although sphere diameter was slightly reduced in S9/S9OX + 4OHT-treated cells compared to controls, still normal numbers of well-formed tumor spheres were present. Importantly, ATP-content and resazurin salt reduction, which are both parameters for cell viability, demonstrated that S9 and S9OX preserved the viability of tumor spheres and strongly inhibited the apoptosis-inducing effect of FOXO3 in this 3D tumor model. The combined data demonstrate that S9 and its oxalate salt S9OX physically interact with the FOXO3-DBD, inhibit FOXO3 transcriptional program and modulate FOXO3 physiologic function in the low micromolar range in living cells.

![Effects of compounds S9/S9OX on FOXO3-induced ROS and sphere growth in 3D cell culture models.\
SH-EP/FOXO3 cells were treated either for four hours with 100 nM 4OHT (**a**) or for two hours with 20 µg/ml etoposide (**b**). 50 µM S9 or S9OX were pre-incubated for 15 min. ROS accumulation was analyzed using CM-H2XROS (500 nM). Images were acquired by live-cell imaging using an Axiovert200M microscope, equipped with a 63x oil objective, bar 20 µm. Shown are representative images (left panel) or densitometric analyses of three independent experiments (more than 15 cells per experiment were quantified) using AxioVision software version 4.8; Significantly different to untreated cells (students t-test, two-tailed): \*\*\*p\<0.001; significantly different between 4OHT-treatment and S9+4OHT or S9OX+4OHT cells: \#\#p\<0.01, \#\#\#p\<0.001; significantly different between etop-treatment and S9+etop or S9OX+etop cells: \#\#\#p\<0.001. 3D spheroids of NB15/FOXO3-GFP cells that express a 4OHT-regulated FOXO3 allele and constitutively EGFP were formed by magnetic bioprinting for 72 hr before treatment with 10 nM 4OHT alone or in combination with 5 µM S9 or S9OX for another 72 hr. After one week, spheroids were analyzed by live cell microscopy and further used for viability analyses. Shown are representative images (**c**) and sphere size/mean diameter (**d**) as well as the number of spheroids per well (**e**) out of three independent experiments. Statistical differences between single 4OHT treatment or combinational treatment were assessed by Mann-Whitney test (two-tailed ^\*\*\*^P\<0.001). Viability of spheroids was assessed by measuring of ATP content (**f**) and resazurin reduction (**g**). Shown are mean values + SD of three independent experiments each performed with spheres of eight different wells. Statistical differences were assessed by students t-test (two-tailed) between 4OHT-DMSO and 4OHT-compound (^\*^P\<0.05, ^\*\*^P\<0.01, \*\*\*\*p\<0.0001).](elife-48876-fig6){#fig6}

Discussion {#s3}
==========

In this manuscript we describe a small compound that inhibits FOXO3 transcriptional activity by direct binding to the FOXO3-DBD. Based on structural data of FOXO3 and FOXO4 we developed six different pharmacophore-models that were then used for in silico screening of structural compound databases. Candidate compounds were tested biochemically by FPA and for biological efficacy in a cell system stably expressing a conditional FOXO3(A3)ERtm allele that can be activated by the addition of 4OHT. We identified compounds that hamper FOXO3-DNA interaction and enter living cells. We selected S9 which also shows increased binding to FOXO3 within FOXO family members ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) for further investigation due to its relatively high solubility in water, established the whole chemical synthesis pathway and synthesized an oxalate salt of S9 with increased solubility in water ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

NMR measurements together with molecular docking simulations suggest that S9 binds to the pocket formed by the C-terminal part of α-helix H3 and the wing W1 ([Figure 2c and d](#fig2){ref-type="fig"}). This region is a crucial part of the DNA binding surface as it includes residues important for DNA recognition: Arg211, His212 and Ser215 from α-helix H3 ([@bib34]) and mutation of His212 also significantly hampers death induction by FOXO3 ([Figure 5a](#fig5){ref-type="fig"}). Furthermore, residues Arg222 and Trp234 from the β-strand S2 at the stem of wing W1 are involved in contact with the phosphate group of the DNA backbone. It is somehow surprising that compound S9 differentially binds to FOXO family members as demonstrated by FPAs ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}) and NMR ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) despite high homology. However, in a recent paper we demonstrated that the solution structures of DBD between these closely related FOXO proteins significantly differ thereby also explaining the differences in compound S9 -- FOXO-DBD interaction ([@bib26]).

Therefore, S9 binding could obstruct FOXO3-DBD interaction with the target DNA, thus blocking its transcriptional activity. The pharmacophore models used for virtual screening all reflected interactions with Arg211 and His212, in addition to (and dependent on the respective model) interactions with Asn208, Ser209, and Ser215. Model 1, which mapped compound S9, for example included hydrophobic interactions with Arg211 and His212 as well as hydrogen bonds with His212 and Asn208. The experimentally identified residues involved in binding overall align well with the in silico modeling and small re-arrangements of the proposed binding mode can be expected in solution.

Gene expression profiling provided an interesting three hours snap-shot on the mRNA changes induced by ectopic FOXO3 activation in presence or absence of compound S9. S9 strongly prevented the induction of FOXO3-induced genes or by its own repressed clusters of highly expressed FOXO3 targets, which is consistent with its interaction to a region in FOXO3-DBD including R211, H212 and S215 which all contribute to helix H3-DNA interaction ([@bib34]). On the other hand, S9 per se strongly induced a cluster of genes that was actively repressed by ectopically switched on FOXO3 suggesting that these genes are permanently repressed by endogenous FOXO3 in manner that requires the DNA-binding domain either for protein-DNA or protein-protein interaction and that this repression is abrogated by S9. A small cluster of genes was identified that was only moderately induced by ectopic FOXO3, but strongly up-regulated in presence of S9. One explanation for this phenomenon might be that DNA-binding independent transactivation by endogenous FOXO3 is further supported by S9 preventing intra-molecular protein-protein interaction of the C-terminal FOXO3 transactivation domain with the FOXO3-DBD as it involves the C-terminus of α-helix H3, which is part of the S9 binding pocket ([@bib35]). These aspects concerning inhibition of intra- or inter-molecular protein-protein interaction at the FOXO3-DBD by S9 are investigated in currently ongoing studies.

Besides genome-wide regulation we tested the effect of S9 and S9OX on FOXO3 transcriptional targets. The BCL2-family members BIM and NOXA are mediators of FOXO3-induced intrinsic cell death and BIM critically triggers transitory accumulation of ROS at the mitochondria, which is counteracted by the parallel induction of the detoxifying protein SESN3 ([@bib8]). DEPP1 sensitizes neuroblastoma cells for ROS and is strongly induced by FOXO3 via three functional FOXO consensus sequences in its promoter ([@bib28]; [@bib29]). We demonstrated that FOXO3 induction of these four *bona fide* targets was efficiently reduced by both S9 and S9OX on mRNA level as well as on protein expression level. To further prove direct inhibition of the FOXO3-DBD-DNA interaction in living cells, ChIP analyses on the four *bona fide* targets was performed which demonstrated that increased FOXO3 binding upon ectopic FOXO3-activation was almost completely abrogated by S9 ([Figure 4e](#fig4){ref-type="fig"}). This was consistent with results from primary FP analysis ([Figure 1f](#fig1){ref-type="fig"}) and dose-dependent repression of promoter activity by S9 and S9OX as demonstrated by luciferase reporter assay ([Figure 4f](#fig4){ref-type="fig"}). If H212 in the S9-interacting region of the FOXO3-DBD is mutated ([Figure 5a](#fig5){ref-type="fig"}) or endogenous FOXO3 is knocked out by CRISPR/Cas9 technology also the physiologic effects of S9 are abrogated ([Figure 5b--f](#fig5){ref-type="fig"}). This suggests that at least in the used model systems, S9 selectively acts via binding to the DBD of FOXO3. Consistent with the repression of target gene regulation, also FOXO3-induced ROS accumulation ([@bib8]; [@bib28]) was efficiently prevented by S9 and S9OX providing evidence that S9 directly interferes with physiological effects of FOXO3 in living cells. Of note S9 might also sterically hamper protein-protein interactions that take place at the FOXO3-DBD such as the binding of the tumor suppressor protein TP53 ([@bib27]; [@bib35]). As affinity measurements using recombinant protein fragments provide only limited information about biologically effective concentrations, we generated magnetic 3D tumor spheres that allowed us on one hand to assess possible long term toxicity of S9/S9OX in 3D culture and on the other to test effective doses of these compounds. S9/S9OX neither reduced sphere-numbers nor diameter when spheres were treated 72 hr with 5 µM of these drugs, but efficiently prevented FOXO3-induced cell death. Interestingly, the growth-inhibitory effects of FOXO3 were only partially inhibited, which corresponds to the observation that gene-dosage effects of FOXO3 lead to, in part, contrary physiological outcomes ([@bib11]).

FOXO transcription factors have been implicated in a plethora of different cellular functions, in cancer immunity where loss of FOXO3 exerts anti-cancer effects, but also hampers other arms of the immune system ([@bib21]), in neuronal development and plasticity ([@bib22]), cancer angiogenesis and metabolism ([@bib41]). This excludes the permanent ablation of FOXO activity in mammals as a therapeutic option. More complexity is added by the fact that the DBD of FOXO transcription factors participates in intra-, but also intermolecular interactions with other cellular key regulators of death and longevity, such as TP53 ([@bib35]) and thereby also affects drug resistance ([@bib27]; [@bib30]) or aging ([@bib1]). Due to its mode of binding, S9 might well interfere with some of these protein-protein interactions. The effect of the small drug-like molecule S9 on specific tissues has to be investigated in detail to evaluate, whether S9 can serve as a chemical starting point for developing FOXO-regulatory compounds that steer distinct target gene subsets/functions of FOXO transcription factors. The advantage of small drug-like molecules such as S9 is the strict control of application-dose and -time and the fact that they are not immunogenic allowing repeated applications -- so dose- and application time can be adjusted to damage cancer cells or boost anti-cancer immunity, but also limit unwanted side effects of FOXO-inhibition on stem cells and other somatic tissues.

Materials and methods {#s4}
=====================

Key Resources Table (see [Supplementary file 2](#supp2){ref-type="supplementary-material"}).

Analysis of FOXO3-DNA interactions and generation of interaction maps {#s4-1}
---------------------------------------------------------------------

The experimentally observed interactions of the FOXO3 consensus sequence DNA strand and the FOXO3-DBD were extracted in LigandScout ([@bib39]) version 3.0 and represented by pharmacophore features. The pdb entry 2UZK ([@bib34]) was loaded into MOE version 11.2011. The protein was protonated using the default settings and interaction maps were generated using the N1:: (sp3 NH with lone pair), O (carbonyl oxygen), and DRY (hydrophobic) probes with −4 kcal/mol, −3.5 kcal/mol, and −2.5 kcal/mol cut-offs, respectively ([Figure 1c](#fig1){ref-type="fig"}).

Docking, pharmacophore modeling, virtual screening, and selection of test compounds {#s4-2}
-----------------------------------------------------------------------------------

GOLD ([@bib17]) version 3.1 was used for docking. Hydrogen atoms were added to the protein and all water molecules and ligands were deleted. The area of 20.0 Å around His212 was defined as binding site and the GoldScore was used for scoring. Up to 10 different docking poses were reported for each input molecule and analyzed using LigandScout version 3.0. Pharmacophore models were created using LigandScout ([@bib39]) version 3.0 based on docking poses of molecules from Drugbank ([@bib38]) version 2.5 (exemplary docking poses of Drugbank molecules used for model generation, are shown in [Figure 1d](#fig1){ref-type="fig"}). Automatically generated models were manually refined to reflect interaction patterns observed in the crystal structure, highlighted by the interaction maps, or involved residues either crucial for binding or which are posttranslational modification sites such as Asn208, Ser209, Arg211, His212, and Ser215. Compound libraries for virtual screening were generated by calculating up to 250 conformations for each molecule in the Specs (version April 2010, [www.specs.net](http://www.specs.net)) and Maybridge (version 2010, [www.maybridge.com](http://www.maybridge.com)) databases. Pharmacophore hits were docked into the binding site using the protocol described above and docking poses were analyzed using LigandScout version 3.0. 76 compounds, for which docking poses reflected the identified interaction patterns, were selected for experimental testing.

Synthesis of S9 and S9OX {#s4-3}
------------------------

The synthesis of S9 and S9OX and all corresponding NMR spectra are described in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Expression and purification of recombinant FOXO3-DBD {#s4-4}
----------------------------------------------------

Recombinant FOXO3-DBD protein was produced as previously described for FOXO4-DBD ([@bib3]). Briefly, DNA encoding human FOXO3-DBD (residues 156--269) was ligated into the pGEX-6P-1 (GE Healthcare), using the BamHI and XhoI sites. FOXO3-DBD was expressed as N-terminal GST-tagged fusion protein in *E. coli* BL21(DE3). Protein expression in LB-media was induced by isopropyl β-D-1-thiogalactopyranoside for 18 hr at 20°C, and the protein was purified using Glutathione Sepharose 4 Fast Flow (Merck, Austria) according to a standard protocol. Protein was dialyzed against buffer containing 20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% (wt/vol) glycerol at pH 7.5. The affinity tag was removed by PreScission Protease cleavage overnight at 4°C (10 U/mg recombinant protein). After the cleavage, FOXO3-DBD was purified by size-exclusion chromatography (HiLoad Superdex 75; GE Healthcare) in 20 mM phosphate buffer containing 50 mM KCl, 2 mM TCEP, and 10% (wt/vol) glycerol at pH 6.5. Isotopically labeled proteins for NMR experiments were expressed using the same procedure in minimal medium with \[^15^N\]NH~4~Cl and/or \[^13^C\]glucose as the sole nitrogen and carbon sources, respectively, and purified as unlabeled FOXO3-DBD.

Fluorescence polarization analyses (FPA) {#s4-5}
----------------------------------------

To determine the binding of compound S9 to FOXO3-DBD in vitro FP-measurements were carried out in black 96-well plates with flat bottom (HVD Life Sciences, Vienna, Austria) in a chameleon plate reader (Hidex, Turku, Finland). For FP-assays, recombinant FOXO3 was only purified via affinity chromatography and gel-filtration chromatography. S9 or S9OX were added to 100 µl reaction mix containing 125 nM FOXO3-DBD and 25 nM FAM-labeled double strand FOXO3 consensus sequence oligonucleotides in assay buffer (20 mM TrisHCl, 100 mM NaCl, 1 mM EDTA, pH 7.5). Positive (only assay buffer and FAM-labeled oligonucleotide) and negative (FOXO3-DBD and FAM-labeled oligonucleotide) controls were analyzed on each plate. Millipolarization values (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

NMR data collection and analysis {#s4-6}
--------------------------------

NMR data were acquired on Bruker Avance III HD 600 MHz and 850 MHz spectrometers both equipped with a ^1^H/^13^C/^15^N cryoprobe at 25°C. The sequence-specific backbone resonance assignment was obtained using a series of standard triple-resonance spectra (HNCO, HN(CA)CO, HNCACB, and CBCA(CO)NH experiments). The obtained assignments were in a good agreement with the sequence-specific backbone NMR assignment obtained for shorter FOXO3-DBD construct ([@bib35]). Chemical shift perturbations (CSPs) were assessed using ^1^H-^15^N heteronuclear single quantum coherence (HSQC) spectra. For these experiments, ^1^H-^15^N HSQC spectra were collected for samples containing 250 μM FOXO3-DBD alone and in the presence of 1.5--7 mM S9OX. All NMR experiments were performed in buffer containing 20 mM sodium phosphate (pH 6.5), 50 mM KCl and 10% D~2~O. STD-NMR experiments were acquired at 25°C using samples containing 15 μM unlabeled FOXO3-DBD in the presence of 1 mM ligand. 10% dimethyl sulfoxide (DMSO) was added to the buffer used in STD experiments with S9 to increase its solubility.

Molecular docking {#s4-7}
-----------------

Docking experiments were performed using Autodock Vina ([@bib33]). The solution structure of FOXO3-DBD (PDB ID: 2K86) and the S9 compound were modeled in Autodock Tools. The search space was defined as a 24 × 22 × 22 Å box centered on the helix H3 of the FOXO3-DBD. Flexible residues were selected based on CSP NMR analysis. The 20 lowest energy solutions were then analyzed and the lowest energy solution consistent with results from both STD and ^1^H-^15^N HSQC experiments was selected as the final pose.

Cell lines, culture conditions, and reagents {#s4-8}
--------------------------------------------

The neuroblastoma cell lines SH-EP/FOXO3 and NB15/FOXO3-GFP were cultured in RPMI1640 (Lonza, Basel, Switzerland) and Phoenix-AMPHO packaging cells and HEK293T cells in DMEM, respectively. All media contained 10% fetal bovine serum (GIBCO BRL, Paisley, UK), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine (Sigma-Aldrich, Vienna, Austria) at 5% CO~2~. All cultures were routinely tested for mycoplasma contamination using the Venor^R^ GeM-mycoplasma detection kit (Minerva Biolabs, Germany). All reagents were purchased from (Merck, Austria) unless indicated otherwise.

Transfections, Retroviral and lentiviral infection and CRISPR/Cas9 mediated knockout {#s4-9}
------------------------------------------------------------------------------------

For the transfection of retro- or lentiviral vectors into packaging cell lines the transfection reagent Lipofectamin 2000 (Thermofisher, USA) was used according to manufacturer's instructions. The retroviral vectors pBabe-puro-HA-FOXO3.A3.ER and pBabe-puro-HA-FOXO3.A3.ER.H212R were described before ([@bib5]). For CRISPR/Cas9 mediated knockout we used the lentiCRISPR/Cas9 v2 vector (Addgene \#52961) ([@bib31]) and inserted the gRNA sequences CACCGCCTGCCATATCAGTCAGCCG or CACCGCAGAGTGAGCCGTTTGTCCG to generate pLentiCRISPR-FOXO3-1 or pLentiCRISPR-FOXO3-2 vector, respectively. Retroviruses (for pBabe vectors) and lentiviruses (pLentiCRISPR vectors) were produced as previously described ([@bib8]). pBabe vectors for expression of conditional FOXO3 or FOXO3-H212R were infected into SH-EP cells generating the SH-EP/FOXO3 and SH-EP/FOXO3-H212R cell lines used in [Figure 5a](#fig5){ref-type="fig"}. pLentiCRISPR-FOXO3-1/2 were infected into SH-EP cells generating cell lines SH-EP/crispFOXO3\#1 and SH-EP/crispFOXO3\#2, respectively. Ectopic expression of FOXO3, FOXO3-H212R or deletion of endogenous FOXO3 was verified by immunoblot.

Promoter activity {#s4-10}
-----------------

Reporter plasmids pGS-c10orf10/DEPP1-luc ([@bib28]), pGL2-luc-Bim ([@bib2]) or pGL3-luc basic were transfected into target cells using JetPrime reagent (Polyplus, Berkeley, USA) and luciferase activity was measured using a Luciferase Assay System kit (Promega, Madison, USA) according to the manufacturer's instructions. The luminescence intensity was measured in a chameleon plate reader (Hidex, Turku, Finland).

Spheroids {#s4-11}
---------

Spheroids were formed by magnetic bioprinting according to manufacturer's instructions (Pelobiotech GmbH, Germany). Spheroids were grown for 72 hr before treatment with 4OHT/4OHT + S9/S9OX. After 72 hr treatment compounds were removed by centrifugation and remaining spheroids were grown for one week. Finally, spheroids were collected and re-plated in 100 µl fresh media into white 96well plates for ATP measurement or clear plates for resazurin reduction. Size was monitored regularly by live-cell microscopy. ATP-amount was measured by CellTiter-Glo-3D-cell-viability-assay according to manufacturer's instruction (Promega, Germany), resazurin salt reduction was assessed *via* fluorescence measurement in a chameleon plate reader (Hidex, Turku, Finland).

Quantitative RT-PCR {#s4-12}
-------------------

To quantify mRNA-levels real-time qPCR was performed using Maxima-SYBR-Green-qPCR-Master-Mix (Thermofisher, Waltham, USA) and GAPDH as reference-gene as previously described ([@bib12]): total-RNA was isolated from 5 × 10^6^ cells using TRI-Reagent (Merck, Vienna, Austria) and 1 µg was reverse-transcribed to cDNA using RevertAid-H-Minus-cDNA-Synthesis Kit (Thermo Scientific, Waltham, USA). Oligonucleotides for BIM, NOXA, DEPP1, SESN3, and GAPDH are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. qRT-PCR-reactions were performed in triplicates in a Bio-Rad-iCycler-instrument and repeated 3-times. After normalization to GAPDH, regulation was calculated between treated and untreated cells.

Microarray expression profiling {#s4-13}
-------------------------------

Generation of the Affymetrix microarray data set was performed at the Expression Profiling Unit of the Medical University Innsbruck according to the manufacturer's protocols. Total RNA was prepared from SH-EP/FOXO3 cells treated for three hours with/without 50 nM 4OHT and/or 50 µM compound S9 and RNA quantity and quality was determined in a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, USA). 250 ng of high quality RNA was processed, hybridized to twelve Human Genome U133 Plus 2.0 arrays (three independent biological replicates per treatment) and scanned according to manufacturer's instructions as described ([@bib32]). The data analysis was performed in R (version). Raw data have been pre-processed using the GCRMA method ([@bib40]).

Immunoblot analyses {#s4-14}
-------------------

Total protein was prepared as described before ([@bib10]). Proteins were separated by SDS-PAGE and blotted on nitrocellulose membrane (GE Healthcare, Chalfot, UK). After blocking, membranes were incubated with primary antibodies directed against Bim, Noxa, DEPP1, SESN3, FOXO3, GAPDH or αTubulin ([Supplementary file 2](#supp2){ref-type="supplementary-material"}), washed and incubated with horseradish-peroxidase conjugated secondary antibody (GE Healthcare, UK). The immunoblots were developed by enhanced chemiluminescence (Merck, Vienna, Austria) according to manufacturer's instructions and analyzed using an AutoChemi detection system (UVP, Cambridge, UK). Densitometry was performed using Labworks software version 4.5 (UVP, UK).

Chromatin-immunoprecipitation (ChIP) {#s4-15}
------------------------------------

ChIP was performed using Magna-ChIP-Kit (Merck, Germany) as described ([@bib28]). 20 µl protein-G-magnetic-beads were coupled to 7.5 µl of FOXO3 antibody (Santa Cruz, Dallas, USA) or control-IgG and incubated with nuclear lysates of shredded DNA from 2 × 10^7^ cells. After precipitation, protein was digested by proteinase-K and DNA was concentrated with ChIP-DNA-Clean- and -Concentrator-Kit (Zymo Research, USA). FOXO3-binding to DNA was quantified by qPCR using promoter-specific primers for FOXO3-targets.

ROS measurements in living cells {#s4-16}
--------------------------------

Cells were grown on LabTek Chamber Slides (Nalge Nunc International, Rochester, USA), coated with 0.1 mg/ml collagen. ROS measurements were performed by incubating the cells with MitoTrackerRed CM-H~2~XROS (Thermofisher, USA) according to the manufacturer's instructions (final concentration 500 nM). Images were acquired with an Axiovert200M microscope (Zeiss, Vienna, Austria). Fluorescence intensity was quantified using Axiovision Software (Zeiss, Vienna, Austria) and relative ROS levels were expressed as % of untreated controls.

Statistics and data analyses {#s4-17}
----------------------------

Data were analyzed in GraphPad Prism seven software. Standard deviation (SD) and Student's t-test (two-tailed, with criteria of significance: \*p\<0.05; \*\*p\<0.01, \*\*\*p\<0.001 and \*\*\*\*p\<0.0001 or ^\#^p\<0.05; ^\#\#^p\<0.01, and ^\#\#\#^p\<0.001) or Mann Whitney U test (\*\*\*p\<0.001) were calculated when applicable.
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**Acceptance summary:**

Both reviewers and myself judge the work to be important and timely for this field. Whether a DBD can be drugged is a burning question, and here you provide a very clear example of how drugs can be developed in this space. The work clearly warrants publication in *eLife* and as a result of the review process the added discussion and data on specificity is essential as drugging protein DNA interfaces is a major challenge in general for the community.

**Decision letter after peer review:**

Thank you for submitting your article \"Modulating FOXO3 transcriptional activity by small, DBD-binding molecules\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Michael Eisen as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Mathias Francois (Reviewer \#1); Ciara Metcalfe (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Both reviewers and myself judge the work to be important and timely for this field. Whether a DBD can be drugged is a burning question, and here you provide a very clear example of how drugs can be developed in this space. The work clearly warrants publication in *eLife*, but it is also essential that you establish the specificity of the compound. Both reviewers and myself noted that the provided data do not unambiguously establish specificity. indeed, as noted by reviewer 2, \"the NMR data (Figure 2---figure supplement 2) suggest an overlap in residues impacted by S9OX in FOXO1 and FOXO3, with distinct regions of the protein impacted in FOXO4\" -- suggesting that the DBD of all these family members may bind to S9OX, to some degree. These data do not support the statement that the NMR data \"suggest selectivity of S9 and S9OX within the FOXO-family of transcription factors.\" It is therefore essential to explore the specificity in more detail. Exploring new chemical spaces to gain in specificity would likely be beyond the scope of this paper, though a great subject to discuss in this paper. However, a solid characterisation of the current 76 compound would establish a benchmark for future studies in this field.

Essential revisions:

I consider all the points raised by reviewers essential, with the exception of developing new variants of S9 that I consider super interesting but out of the scope of this paper. following is a summary of the concerns to address.

1\) Selectivity issue: following is a list of the points raised by the two reviewers. I would like this point to be clarified in a revised work. Achieving selectivity is not important for publication but the selectivity must be known and documented.

2\) Use of 4 OHT and doses of S9: several critical issues need to be documented here with identical doses of the compound and synergistic effects must be explored.

3\) Cellular source of FOXO3: overexpression of FOXO3 is a problem and one would want to see some other approach. Reviewer 2 in her point 3 suggest a great possibility that would offer an orthogonal system to perform this study.

Reviewer \#1:

This work by Psenakova and colleagues is really exciting and will directly contribute to the emerging and expanding field of drugging transcription. The molecular strategy chosen by the author is to target the DNA binding domain of FOXO3 transcription factor, using a pipeline that relies on: 1) an in silico-based approach (docking FOX/DNA to identify hot spot- generate 76 hits for in vitro testing via virtual screening using 2 chemical databases). 2) modelling of protein DNA interface to identify putative residues involved in small compound interaction. 3) combination of in vitro homogenous assay (FP) and in vitro cell-based assay with transcriptomics and tumour sphere assay as a readout for FOXO3 activity to validate inhibitor activity in living cells.

Overall the quality of the data is high and the manuscript clearly written. There is no doubt that the identified compound (S9) has some biological effects, at least in part mediated by FOXO3 inhibition, however the on-target engagement on FOXO3 lack some experimental evidences. With the current data set as it stands one cannot definitely come to the conclusion that S9 mostly acts via FOXO3 inhibition and interference of DNA binding.

Key experimental evidences missing to support the claims:

1\) The rationale is to target the DNA binding activity of FOXO3. Aside from the FP data there is no evidence that S9 acts with this mode of action in cells to interfere with gene transcription. To address this the authors would need to perform ChiPSeq for FOXO3 in presence or absence of the compound and show that genome wide binding locations are interfered with by S9. At least the author should be able to provide some evidence on a subset of known FOXO3 direct target genes that FOXO3 binding is altered at known binding sites -- This can be done by ChIP-qPCR analysis.

2\) It would be helpful to perform thermal stability assay in presence of FOXO3 or a FOXO3 mutant (Arg 211, His 212, Ser215 amino acid thought to be involved with S9 interaction) with and without S9. This to further support the modelling data for compound/protein interaction.

3\) It is difficult to understand how S9 achieve such a high level of selectivity to FOXO3 at least in FP while targeting such a highly conserved region as the DNA binding domain of FOX protein. Of note the FP experiments run for FOXO3 and other FOXO protein use different concentrations of S9 molecules (250nM for FOXOs vs. 500nM for FOXO3). To be able to compare selectivity it is necessary to perform the same dose response of S9 across all the FOXO protein.

4\) The work rely solely on the use of 1 compound, it is therefore difficult to assess the level of selectivity of this molecular space. How are other compounds closely related (with a similar pharmacophore) but with no predicted DNA binding activity behave (at least in FP). Can S9 affect FOXM1 DNA binding activity? These data would help to assess specificity and efficacy of S9 as a protein/DNA disruptor.

5\) It Is possible that S9 and 4-OHT have a synergic or additive effect on FOXO3 gene regulatory network. The analysis of the RNAseq data set should revised and include an analysis of DEseq for -4OHT with -4OHT+S9. This would be useful to assess the effect of the inhibitor on endogenous FOXO3 activity.

6\) The authors highlight that the SH-EP neuroblastoma cell line used in this work has some level of FOXO3 activity. In the tumour sphere assay there is no effect of S9 in condition without 4OHT. It seems that S9 only works in over-expression condition- if there is endogenous FOXO3 expression in SHEP cells why is there no effect of S9?

Reviewer \#2:

Hagenbuchner et al. describe inhibition of the transcription factor FOXO3 by small molecule targeting of its DNA-binding domain. Therapeutic targeting of transcription factors is highly desirable, but remains a significant challenge. Practical advancements in this area are thus potentially impactful, and the topic of this study is thus relevant for publication in *eLife*. However, there are some key elements of the work where improvements are warranted:

1\) -- Given that a major concern of small molecule perturbation of DNA-binding is the specificity of this approach, it is important to clearly establish selectivity of S9/S9OX, across the FOXO family and beyond. While the fluorescence polarization assay measuring binding of FOXO-DBD to labelled oligo provides some evidence of potential selectivity (though the result for FOXO4 is borderline), the NMR data (Figure 2---figure supplement 2) suggests an overlap in residues impacted by S9OX in FOXO1 and FOXO3, with distinct regions of the protein impacted in FOXO4 -- suggesting that the DBD of all these family members may bind to S9OX, to some degree. These data do not support the statement that the NMR data \"suggests selectivity of S9 and S9OX within the FOXO-family of transcription factors.\"

2\) -- Given the above, it would be useful to see the primary biochemical validation data (i.e. fluorescence polarization assay) for the 76 virtual hits that were experimentally tested, to understand the dynamic range, sensitivity and specificity of the in vitro screening assay e.g. what did an unconfirmed hit look like, vs. S9? Ideally, a secondary screen would have been performed against an unrelated DBD -- was this done?

3\) -- The mRNA expression data showing attenuation of 4OHT-induced transcription by S9(OX), and the CHIP data showing a prevention of 4OHT-induced DNA binding of FOXO3 are highly encouraging. However, a limitation is that much of the functional data is in the context of exogenously expressed, ER-tagged, mutant FOXO3. Activity states of endogenous FOXO3 can be \"toggled\" using PI3K/AKT inhibitors (e.g. Santo et al., Cancer Research, 2013). An assessment of how S9(OX) impacts endogenous FOXO3-mediated transcription and DNA-binding under these conditions would provide more compelling support for S9 mechanism.

4\) -- For the viability experiments on the NB15 cells, the S9 dose is dropped to 5µM, while the FOXO3-specific pathway assessments were conducted at 50µM -- it would be worthwhile to show a dose response of both the transcriptional and physiological effects to demonstrate that the physiological consequences of S9-treatment are due to an on-target effect on transcription i.e. the transcriptional and physiological phenotypes should occur/arise at similar drug concentrations.

10.7554/eLife.48876.sa2

Author response

> Summary:
>
> Both reviewers and myself judge the work to be important and timely for this field. Whether a DBD can be drugged is a burning question, and here you provide a very clear example of how drugs can be developed in this space. The work clearly warrants publication in eLife, but it is also essential that you establish the specificity of the compound. Both reviewers and myself noted that the provided data do not unambiguously establish specificity. indeed, as noted by reviewer 2, \"the NMR data (Figure 2---figure supplement 2) suggest an overlap in residues impacted by S9OX in FOXO1 and FOXO3, with distinct regions of the protein impacted in FOXO4\" -- suggesting that the DBD of all these family members may bind to S9OX, to some degree. These data do not support the statement that the NMR data \"suggest selectivity of S9 and S9OX within the FOXO-family of transcription factors.\" It is therefore essential to explore the specificity in more detail. Exploring new chemical spaces to gain in specificity would likely be beyond the scope of this paper, though a great subject to discuss in this paper. However, a solid characterisation of the current 76 compound would establish a benchmark for future studies in this field.

We now revised Figure 1 showing the whole *in silico* screening strategy that was previously split between Figure 1 and Figure 1---figure supplement 1 and now added the screening data (fluorescence polarization assay (FPA) and flow cytometric analyses) for the 76 candidate compounds as novel Figure 1---figure supplement 1. We also explain there, how the different compounds were clustered according to the combined FP- and cytometry live/dead screening results. We replaced also the previous FP graph (now Figure 1F) and cell based validation assay (now Figure 1G) by experiments showing dose dependent effects of S9 and S9ox. In Figure 1G we used a constant concentration of 4OHT to activate ectopic FOXO3, varied the concentration of S9 from 3.1 µM to 50 µM and nicely demonstrate that S9 and S9OX inhibit cell death in a dose dependent manner.

> Essential revisions:
>
> I consider all the points raised by reviewers essential, with the exception of developing new variants of S9 that I consider super interesting but out of the scope of this paper. following is a summary of the concerns to address.
>
> 1\) Selectivity issue: following is a list of the points raised by the two reviewers. I would like this point to be clarified in a revised work. Achieving selectivity is not important for publication but the selectivity must be known and documented.
>
> 2\) Use of 4 OHT and doses of S9: several critical issues need to be documented here with identical doses of the compound and synergistic effects must be explored.

Now, we also performed a dose-response analysis with constant concentrations of S9 and varying doses of 4OHT, as suggested by the reviewers. This demonstrates that the compounds S9 and S9OX do not induce programmed cell death per se and that above a certain level of activation of ectopic FOXO3 (i.e. approx. 20 nM 4OHT) cell death induction reaches a plateau in this model system within 48 hours. As S9 inhibits FOXO3 and also ectopic FOXO3-induced cell death triggered by 4OHT, synergistic effects between 4OHT and S9 cannot be detected.

> 3\) Cellular source of FOXO3: overexpression of FOXO3 is a problem and one would want to see some other approach. Reviewer 2 in her point 3 suggest a great possibility that would offer an orthogonal system to perform this study.

Selectivity issue and cellular source of FOXO3:

We agree with the editors and the reviewers that the selectivity issue / possible off target effects of S9 were not fully investigated in the previous manuscript. In addition, the reviewers noted correctly that all biological studies were performed using a conditional ectopically expressed FOXO3 construct that might behave different to endogenous FOXO3.

We tried to address these questions in detail and generated cell lines where endogenous FOXO3 was homozygous deleted by CRISPR/Cas 9 technology and cell lines carrying a conditional FOXO3 allele with a mutation at histidine H212 (H212 is central to the S9 binding pocket and showed a significant shift upon S9 binding, see Figure 2B and C). Cell biological experiments demonstrate that FOXO3 is essential for the induction of target genes Bim, DEPP1 and SESN3 under low serum conditions or genotoxic stress (Figure 5B-F). Upon deletion of endogenous FOXO3 the compound S9 does not repress above FOXO3 targets in response to serum withdrawal and / or etoposide treatment any longer. This proves that S9 exerts its inhibitory effect exclusively via endogenous FOXO3. Importantly, mutation of H212 markedly inhibits the death-inducing abilities of ectopic FOXO3, but completely abrogates S9 effects suggesting that H212 is essential for S9 -- FOXO3 interaction. We now added a complete new Figure 5 to the manuscript showing these data.

To address the relevance of endogenous FOXO3 for the growth of tumor spheroids we cultured NB15/crispFOXO3 cells (FOXO3 knockout) for three days with/without S9 and observed that knockout of endogenous FOXO3 has no significant effect on viability of 3D tumor spheroids.

To address possible binding of S9 beyond FOXO family members we performed FPAs with recombinant FOXM1 protein (Figure 1---figure supplement 2B) and the suggested Differential Scanning Fluorimetry (DSF) assays (reviewer \#1, point 3) with the newly generated FOXO3 mutant (Arg211, His212 and Ser215). Like for the FOXO-family member FOXO6, S9 did not affect FOXM1-DBD -- DNA interaction as measured by FPA, suggesting that S9 is not effective on FOXM1. DSF analyses did not provide clear results which might be explained by too low sensitivity of this method. Nevertheless, a subtle stabilization was observed for the wildtype and a subtle destabilisation for the triple mutant.

In an ongoing project we are also investigating the chemical spaces and are trying to generate improved chemical derivatives.

> Reviewer \#1:
>
> *This work by Psenakova and colleagues is really exciting and will directly contribute to the emerging and expanding field of drugging transcription. The molecular strategy chosen by the author is to target the DNA binding domain of FOXO3 transcription factor, using a pipeline that relies on: 1) an in silico-based approach (docking FOX/DNA to identify hot spot- generate 76 hits for* in vitro *testing via virtual screening using 2 chemical databases). 2) modelling of protein DNA interface to identify putative residues involved in small compound interaction. 3) combination of* in vitro*homogenous assay (FP) and* in vitro cell-based assay with transcriptomics and tumour sphere assay as a readout for FOXO3 activity to validate inhibitor activity in living cells.
>
> Overall the quality of the data is high and the manuscript clearly written. There is no doubt that the identified compound (S9) has some biological effects, at least in part mediated by FOXO3 inhibition, however the on-target engagement on FOXO3 lack some experimental evidences. With the current data set as it stands one cannot definitely come to the conclusion that S9 mostly acts via FOXO3 inhibition and interference of DNA binding.
>
> Key experimental evidences missing to support the claims:
>
> 1\) The rationale is to target the DNA binding activity of FOXO3. Aside from the FP data there is no evidence that S9 acts with this mode of action in cells to interfere with gene transcription. To address this the authors would need to perform ChiPSeq for FOXO3 in presence or absence of the compound and show that genome wide binding locations are interfered with by S9. At least the author should be able to provide some evidence on a subset of known FOXO3 direct target genes that FOXO3 binding is altered at known binding sites -- This can be done by ChIP-qPCR analysis.

Figure 4E shows a ChIP-qPCR analysis for the *bonafide* FOXO3 target genes Bim, Noxa, SESN3 and DEPP1 demonstrating that S9 directly interferes with DNA binding at the genomic level.

> 2\) It would be helpful to perform thermal stability assay in presence of FOXO3 or a FOXO3 mutant (Arg 211, His 212, Ser215 amino acid thought to be involved with S9 interaction) with and without S9. This to further support the modelling data for compound/protein interaction.

As suggested by the reviewer, we prepared the FOXO3-DBD triple mutant (R211A, H212A, S215A) and compared its thermal stability with FOXO3-DBD WT in the absence and presence of 500 μm S9OX using differential scanning fluorimetry (DSF, thermal shift assay). As noticed, the sensitivity of this technique is not high enough to detect weak interaction between FOXO3-DBD and S9. Nevertheless, we observed subtle stabilization in the case of WT and subtle destabilization for the mutant, however in both cases observed changes in Tm were not statistically significant. Listed values are mean +/- SD from six measurements. Protein concentration was 15 µM. In addition, we also generated cell lines expressing a conditional FOXO3-H212R mutant allel and tested the effect of this mutant in presence or absence of S9. As shown in Figure 5A, this mutant has residual cell death inducing activity, which is not affected by S9 or S9OX any longer. As death induction in this cell model depends on the transcriptional induction of Bim (Hagenbuchner et al., 2012) these data suggest that the residual transcriptional activity of this mutant is not affected by S9 due to significant changes in the S9 binding pocket that hamper S9 binding.

> 3\) It is difficult to understand how S9 achieve such a high level of selectivity to FOXO3 at least in FP while targeting such a highly conserved region as the DNA binding domain of FOX protein.

Although the DBD is highly conserved within the FOXO family members detailed analyses of NMR solution structures of FOXO1-DBD, FOXO3-DBD and FOXO4-DBD demonstrates that the positions of helices H1, H2 and H3 and the interactions between hydrophobic residues at the interface between the N-terminal segment, the H2-H3 loop and the recognition helix H3 differ within the FOXO protein family members (Psenakova et al., 2019). This may explain why compound S9 shows different effects in comparative FPAs and targets FOXO family members to different extent.

> Of note the FP experiments run for FOXO3 and other FOXO protein use different concentrations of S9 molecules (250nM for FOXOs vs. 500nM for FOXO3). To be able to compare selectivity it is necessary to perform the same dose response of S9 across all the FOXO protein.

We would like to point out that in Figure 1---figure supplement 2A the identical conditions (i.e. concentrations of FOXO-proteins, FAM-labelled oligonucleotide and S9 (250nM)) were used for all proteins. Only in the FPA shown in previous Figure 1 we had a concentration of 500 nM. Nevertheless, we now also replaced the FPA in Figure 1 by a graph showing dose-dependent effects of S9 (range between 250 nM and 1 µM).

> 4\) The work rely solely on the use of 1 compound, it is therefore difficult to assess the level of selectivity of this molecular space. How are other compounds closely related (with a similar pharmacophore) but with no predicted DNA binding activity behave (at least in FP).

We now added, as also requested by reviewer \#2, the data on the FPA / live/dead validation process as Figure 1---figure supplement 1 to the manuscript showing 76 candidate compounds identified by pharmacophore modelling / in silico screening. Despite all of these candidates were selected by the pharmacophore models only 11 of them displaced the consensus oligonucleotide in the FPA. In an ongoing project we are now investigating in detail the chemical spaces that define binding of S9 and we also try to improve the affinity / biological efficacy.

> Can S9 affect FOXM1 DNA binding activity? These data would help to assess specificity and efficacy of S9 as a protein/DNA disruptor.

We expressed and purified recombinant FOXM1-DBD (222-360) protein and tested S9 at a concentration of 500 µM in parallel in FOXO3-FPA and FOXM1-FPA. As shown in Figure 1---figure supplement 2B, similar to FOXO6 the compound S9 does not interfere with binding of FOXM1 to its consensus sequence.

> 5\) It Is possible that S9 and 4-OHT have a synergic or additive effect on FOXO3 gene regulatory network. The analysis of the RNAseq data set should revised and include an analysis of DEseq for -4OHT with -4OHT+S9. This would be useful to assess the effect of the inhibitor on endogenous FOXO3 activity.

We addressed this issue in cell biological experiments by either constant 4OHT concentrations and varying S9 or S9OX (Figure 1G) or constant S9 concentration and varying 4OHT. Of note, as S9 or S9OX do not affect viability per se, on a physiologic level no synergism between 4OHT and S9 can be observed. We now mentioned in the text that S9 by its own caused repression of 412 genes (subsection "Compounds S9 and S9OX affect the FOXO3 transcriptional program". To further assess the effect of S9 on endogenous FOXO3 we generated FOXO3 knock out cells using CRISPR/Cas9 technology and analyzed the effect of serum withdrawal and/or etoposide treatment on target gene regulation in presence or absence of S9 and S9OX. The combined results are shown in Figure 5B-F and demonstrate that knockout of endogenous FOXO3 also abrogates the effects of S9 on gene regulation of these FOXO target proteins in response to growth factor withdrawal and/or genotoxic stress.

> 6\) The authors highlight that the SH-EP neuroblastoma cell line used in this work has some level of FOXO3 activity. In the tumour sphere assay there is no effect of S9 in condition without 4OHT. It seems that S9 only works in over-expression condition- if there is endogenous FOXO3 expression in SHEP cells why is there no effect of S9?

The heatmap in Figure 3A demonstrates that S9 affects the gene-regulation patterns also in the absence of 4OHT (comparison between DMSO and S9) but apparently this does not affect genes that are critical for survival and/ or proliferation. The fact that FOXO3 is dispensable at normoxic conditions (Hagenbuchner et al., 2017) for the survival of SH-EP as well as of NB15 neuroblastoma cells that we used for formation of tumor spheres is further demonstrated by the fact that FOXO3 knockout cells show no reducedproliferation or viability (Figure 5B-F). In Figure 5 we also demonstrate that compound S9 and S9OX exert pronounced effects on endogenous gene regulation under conditions of serum withdrawal and/or genotoxic stress -- so the compound acts also on endogenous FOXO3.

> Reviewer \#2:
>
> Hagenbuchner et al. describe inhibition of the transcription factor FOXO3 by small molecule targeting of its DNA-binding domain. Therapeutic targeting of transcription factors is highly desirable, but remains a significant challenge. Practical advancements in this area are thus potentially impactful, and the topic of this study is thus relevant for publication in eLife. However, there are some key elements of the work where improvements are warranted:
>
> 1\) Given that a major concern of small molecule perturbation of DNA-binding is the specificity of this approach, it is important to clearly establish selectivity of S9/S9OX, across the FOXO family and beyond. While the fluorescence polarization assay measuring binding of FOXO-DBD to labelled oligo provides some evidence of potential selectivity (though the result for FOXO4 is borderline), the NMR data (Figure 2---figure supplement 2) suggests an overlap in residues impacted by S9OX in FOXO1 and FOXO3, with distinct regions of the protein impacted in FOXO4 -- suggesting that the DBD of all these family members may bind to S9OX, to some degree. These data do not support the statement that the NMR data \"suggests selectivity of S9 and S9OX within the FOXO-family of transcription factors.\"

*2) Given the above, it would be useful to see the primary biochemical validation data (i.e. fluorescence polarization assay) for the 76 virtual hits that were experimentally tested, to understand the dynamic range, sensitivity and specificity of the* in vitro *screening assay e.g. what did an unconfirmed hit look like, vs. S9? Ideally, a secondary screen would have been performed against an unrelated DBD -- was this done?*

Following the reviewer's suggestions we now included the results of the primary biochemical validation screen and the live/dead screen of the 76 candidate compounds as Figure 1---figure supplement 1. Although the FPA demonstrated that DNA-interaction of the FOXO family member FOXO6 was not affected by S9 we also performed FPA assays with recombinant FOXM1-DBD protein. The data suggest that S9 does not affect the interaction of FOXM1-DBD with its cognate consensus sequence (Figure 1---figure supplement 2B). In addition, we also generated cell lines with a conditional FOXO3-H212R allele. In this FOXO3 allele the H212, which had the most pronounced shift in NMR upon S9 binding, is mutated. This mutant shows strongly reduced, but still visible induction of cell death (Figure 5A), which depends on the induction of Bim in these neuroblastoma cells (Hagenbuchner et al., 2012). Importantly, in these cells the addition of S9 does not affect cell death at all, suggesting that the loss of H212 in FOXO3 prevents S9 -- FOXO3-DBD interaction.

To address the selectivity issue we knocked out endogenous FOXO3 by CRISPR/Cas9 technology, applied growth factor withdrawal and/or genotoxic stress by etoposide treatment which both trigger activation of endogenous FOXOs (Hagenbuchner et al., 2012; Hagenbuchner et al., 2013). S9 and S9OX block the activation of reporter plasmids for Bim and DEPP1 promoter (Figure 5B, C), as well as the induction of endogenous Bim, DEPP1 and SESN3 (Figure 5D-F). Importantly, in FOXO3 knockout cells S9 did not show any inhibitory effect, thereby demonstrating that S9 / S9OX acts onto stress- and growth factor withdrawal-induced genes via FOXO3.

> 3\) The mRNA expression data showing attenuation of 4OHT-induced transcription by S9(OX), and the CHIP data showing a prevention of 4OHT-induced DNA binding of FOXO3 are highly encouraging. However, a limitation is that much of the functional data is in the context of exogenously expressed, ER-tagged, mutant FOXO3. Activity states of endogenous FOXO3 can be \"toggled\" using PI3K/AKT inhibitors (e.g. Santo et al., Cancer Research, 2013). An assessment of how S9(OX) impacts endogenous FOXO3-mediated transcription and DNA-binding under these conditions would provide more compelling support for S9 mechanism.
>
> 4\) For the viability experiments on the NB15 cells, the S9 dose is dropped to 5µM, while the FOXO3-specific pathway assessments were conducted at 50µM -- it would be worthwhile to show a dose response of both the transcriptional and physiological effects to demonstrate that the physiological consequences of S9-treatment are due to an on-target effect on transcription i.e. the transcriptional and physiological phenotypes should occur/arise at similar drug concentrations.

This is difficult to address because the physiological outcome of FOXO3 activation is not monogenic but a balance in the regulation of different genes that are also activated to different extent (Hagenbuchner and Ausserlechner, 2013). Therefore, the induction (or repression by S9 / S9OX) of one gene might not correlate directly with the physiologic outcome. To demonstrate dose-dependent inhibition of FOXO3-induced cell death we now included a dose-response curve as Figure 1G. We hope that the reviewer agrees with us that the selective knockout of FOXO3 is a good strategy to demonstrate that S9 acts via FOXO3-induced transcription. Please note that serum withdrawal also increases the expression of FOXO3 target genes, primarily involved in stress-detoxification (Figure 5D-F) in the FOXO3 knockout background suggesting that another serum responsive regulator induces the transcription and that this induction is not affected by S9 or S9OX.
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